Telehealth company Hims & Hers Health Inc. said late Monday it is in “active discussions” with Denmark’s Novo Nordisk A/S to ...

Pfizer filed an antitrust lawsuit on Monday accusing Danish drugmaker Novo Nordisk of structuring its $9 billion bid for ...

There’s plenty of reason to remain bullish on Novo Nordisk. Even with the challenges it has faced recently, the company ...

Denmark's Novo Nordisk launched a rival bid for U.S. obesity biotech firm Metsera on Thursday, hijacking an offer from Pfizer ...

Denmark's Novo Nordisk launched a rival bid for U. obesity biotech firm Metsera on Thursday, hijacking an offer from Pfizer ...

The Wegovy and Ozempic maker’s offer comes after Pfizer last month agreed to a lower deal to acquire the Nasdaq-listed ...

Shares of Hims & Hers Health ($HIMS) rallied in pre-market hours on Tuesday after management said it’s in discussions with ...

Hims & Hers continues to sell compounded semaglutide, the active ingredient in Novo’s Wegovy and Ozempic drugs, and these ...

LONDON (Reuters) -Novo Nordisk's new CEO is set to face intense investor scrutiny this week as the Wegovy-maker shakes up its ...

Hims & Hers said that the discussions with Novo Nordisk (DK:NOVO.B) are ongoing, that "no definitive agreement" has been reached, and that the two companies may not reach one. Nonetheless, Hims & Hers ...

Novo Holdings, which controls obesity drugmaker Novo Nordisk, is sharpening its focus on India, targeting single-specialty ...

Leading global healthcare company Novo Nordisk announces the launch of Wegovy® in Hong Kong, now available at private clinics and selected pharmacies. Clinically proven for long-term weight management ...